Patents by Inventor Christopher G. Kevil

Christopher G. Kevil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11510925
    Abstract: The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 29, 2022
    Assignee: Board of Supervisors of Louisiana State University
    Inventors: Christopher G. Kevil, Rodney Shackelford
  • Patent number: 11116731
    Abstract: A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: September 14, 2021
    Assignee: Brd. of Sup. of LSU and A &M College
    Inventors: Christopher G. Kevil, Paari Dominic
  • Publication number: 20200171041
    Abstract: The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
    Type: Application
    Filed: November 13, 2019
    Publication date: June 4, 2020
    Inventors: Christopher G. KEVIL, Rodney SHACKELFORD
  • Publication number: 20190365669
    Abstract: A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 5, 2019
    Inventors: Christopher G. KEVIL, Paari DOMINIC
  • Patent number: 10254262
    Abstract: A hydrogen sulfide (H2S) detecting apparatus for measuring the concentrations of hydrogen sulfide species in a given sample is disclosed. The hydrogen sulfide detecting apparatus can comprise a plurality of reaction chambers separated from a plurality of trapping chambers by a (H2S) permeable membrane, with the reaction chambers and trapping chambers each having buffer component(s) and/or reactive agents that expose the incoming sample to a particular pH and chemical environment in order to allow for the selective liberation and trapping of hydrogen sulfide from the sample.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 9, 2019
    Assignees: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Louisiana Tech University
    Inventors: Christopher G. Kevil, John D. Glawe, Clifton F. Frilot, Leland Weiss
  • Patent number: 9599602
    Abstract: Hydrogen sulfide (H2S) levels in plasma are useful in diagnosing cardiovascular disease. The ratio of H2S to NO in plasma is useful in diagnosing peripheral artery disease.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: March 21, 2017
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher G. Kevil, Elvis A. Peter, Xinggui Shen
  • Patent number: 9465024
    Abstract: A method to measure all relevant biologic hydrogen sulfide pools, namely free hydrogen sulfide, acid-labile sulfide, and bound sulfane sulfur, has been developed. This new method involves selective liberation, trapping and derivatization of labile hydrogen sulfide. The total labile sulfide, including the contribution of the bound sulfane sulfur pool, the acid-labile pool, and free H2S, was measured by incubating the sample with a reducing agent, TCEP (Tris(2-carboxyethyl)phosphine hydrochloride), to reduce disulfide bonds in an acid solution. This method was used to measure the three sulfide pools in blood samples from mice and from humans. This method can be used for research, environmental, and clinical diagnostic purposes in determining hydrogen sulfide bioavailability in biological or other samples.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 11, 2016
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Christopher G. Kevil, Xinggui Shen, Elvis A. Peter
  • Publication number: 20160041139
    Abstract: A hydrogen sulfide (H2S) detecting apparatus for measuring the concentrations of hydrogen sulfide species in a given sample is disclosed. The hydrogen sulfide detecting apparatus can comprise a plurality of reaction chambers separated from a plurality of trapping chambers by a (H2S) permeable membrane, with the reaction chambers and trapping chambers each having buffer component(s) and/or reactive agents that expose the incoming sample to a particular pH and chemical environment in order to allow for the selective liberation and trapping of hydrogen sulfide from the sample.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 11, 2016
    Inventors: Christopher G. Kevil, John D. Glawe, Clifton F. Frilot, Leland Weiss
  • Publication number: 20150056713
    Abstract: A method to measure all relevant biologic hydrogen sulfide pools, namely free hydrogen sulfide, acid-labile sulfide, and bound sulfane sulfur, has been developed. This new method involves selective liberation, trapping and derivatization of labile hydrogen sulfide. The total labile sulfide, including the contribution of the bound sulfane sulfur pool, the acid-labile pool, and free H2S, was measured by incubating the sample with a reducing agent, TCEP (Tris(2-carboxyethyl)phosphine hydrochloride), to reduce disulfide bonds in an acid solution. This method was used to measure the three sulfide pools in blood samples from mice and from humans. This method can be used for research, environmental, and clinical diagnostic purposes in determining hydrogen sulfide bioavailability in biological or other samples.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 26, 2015
    Applicant: LSU System Office
    Inventors: Christopher G. Kevil, Xinggui Shen, Elvis A. Peter